PEABODY, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), a provider of leading-edge healthcare and security solutions, today announced that its stockholders have approved the previously announced merger agreement under which an affiliate of Altaris Capital Partners, LLC will acquire all of the outstanding shares of Analogic for $84.00 per share in cash, or approximately $1.1 billion on a fully diluted basis. The approval of the stockholders of Analogic was a condition to the closing of the merger agreement, which has now been satisfied.
Of the votes cast at Analogic’s special meeting held on June 21, 2018, 97.66% voted in favor of the merger agreement, which equates to 79.44% of all outstanding shares.
The transaction is expected to close on June 22, 2018. As previously announced, Analogic was granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the pending transaction. Upon the completion of the transaction, Analogic will become a privately held company and shares of Analogic’s common stock will no longer be listed on any public market.
About Analogic
Analogic provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. Analogic is recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Analogic’s market-leading ultrasound systems, led by its flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Analogic’s advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI), and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com.
